McKesson to buy Precision Medicine Group for $2.25bn

US-based healthcare services provider McKesson has agreed to acquire Precision Medicine Group for $2.25bn. McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services. Precision Medicine Group will operate within McKesson once the transaction receives final regulatory and closing approvals. Credit: Piotr Swat / Shutterstock.com. US-based healthcare services provider McKesson has agreed to buy Precision Medicine Group for $2.25bn. McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services. NPVM: Merck & Co Inc's MK-0616 Reports Immuno-oncology (IO) Thematic Intelligence Go deeper with GlobalData The gold standard of business intelligence. Combine…

Source: Pharmaceutical Technology